Daxor Announces New Clinical Studies Validate BVA Technology In High-Acuity Heart Failure Populations To Enhance Care At HFSA 2026 Annual Scientific Meeting

Benzinga · 1d ago

Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announced significant clinician interest and compelling clinical validation following the Heart Failure Society of America (HFSA) 2026 Annual Scientific Meeting.

Strong clinician engagement at the conference underscored the need for Daxor’s next-generation blood volume analysis (BVA™) radiopharmaceutical diagnostic system, driven by its streamlined workflow, rapid result delivery, and industry-leading accuracy exceeding 95%. Daxor highlighted the opportunity that precision volume measurement has to empower effective diagnosis and optimal treatment pathways for patients with heart failure, a syndrome marked by significant volume derangements that are challenging to assess with proxy markers.

Additionally, new clinical data presented by researchers from Banner University Medical Center further validated the essential clinical value of BVA across complex, high-cost patient populations:

  • Superior Diagnostic Precision in High-Acuity Patients: The study, "Inpatient Blood Volume Analysis in Left Ventricular Assist Device and Total Artificial Heart Patients," demonstrated that severe heart failure patients with mechanical heart pumps suffer from complex fluid overload and true anemia that standard bedside examinations miss in 38% of cases. Direct BVA measurement unmasked these hidden derangements, enabling care teams to optimize medical therapy and achieve a statistically significant improvement in patient diuresis (p = 0.02).
  • Uncovering Critical Heart Failure Volume Targets: The 238-patient study, "Heterogeneity Of Volume Derangements In Advanced Heart Failure: Unmasking Red Blood Cell Volume As A Hidden Driver Of Plasma Volume Phenotypes," concluded that the use of BVA offered the opportunity to "enhance clinical decision making, guide treatment, and improve outcomes." The study proved BVA’s unique ability to diagnose a critical, previously unmeasurable condition—Plasma Volume Reserve (PVR) depletion—driven by hidden red blood cell abnormalities and capillary leak. The findings solidify BVA as a unique diagnostic tool for precision heart failure care.